PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.78%
Revenue growth similar to ADI's 6.61%. Walter Schloss would see if both companies share industry tailwinds.
10.01%
Gross profit growth 1.25-1.5x ADI's 8.73%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
15.16%
EBIT growth 1.25-1.5x ADI's 12.04%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
14.13%
Operating income growth 1.25-1.5x ADI's 12.04%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
10.15%
Net income growth 1.25-1.5x ADI's 8.85%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
10.00%
EPS growth similar to ADI's 9.52%. Walter Schloss would assume both have parallel share structures and profit trends.
9.63%
Similar diluted EPS growth to ADI's 9.62%. Walter Schloss might see standard sector or cyclical influences on both firms.
0.11%
Slight or no buybacks while ADI is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.21%
Slight or no buyback while ADI is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
0.10%
Dividend growth under 50% of ADI's 11.13%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
14.65%
OCF growth under 50% of ADI's 72.07%. Michael Burry might suspect questionable revenue recognition or rising costs.
12.52%
FCF growth under 50% of ADI's 87.82%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
65.88%
Similar 10Y revenue/share CAGR to ADI's 70.85%. Walter Schloss might see both firms benefiting from the same long-term demand.
52.11%
5Y revenue/share CAGR at 50-75% of ADI's 78.61%. Martin Whitman would worry about a lagging mid-term growth trajectory.
20.69%
3Y revenue/share CAGR above 1.5x ADI's 10.27%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
320.99%
10Y OCF/share CAGR above 1.5x ADI's 204.52%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
115.68%
5Y OCF/share CAGR 1.25-1.5x ADI's 92.54%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
22.95%
3Y OCF/share CAGR above 1.5x ADI's 2.92%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
259.89%
Net income/share CAGR above 1.5x ADI's 42.21% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
156.30%
5Y net income/share CAGR 1.25-1.5x ADI's 107.58%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
45.48%
3Y net income/share CAGR above 1.5x ADI's 11.81%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
28.12%
Below 50% of ADI's 176.22%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
21.70%
Below 50% of ADI's 109.01%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
11.02%
3Y equity/share CAGR at 50-75% of ADI's 15.43%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
686.53%
10Y dividend/share CAGR above 1.5x ADI's 213.49%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
168.06%
5Y dividend/share CAGR above 1.5x ADI's 63.95%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
64.54%
3Y dividend/share CAGR 1.25-1.5x ADI's 43.32%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
0.44%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-1.80%
Inventory is declining while ADI stands at 3.65%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.91%
Asset growth above 1.5x ADI's 0.69%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
9.59%
BV/share growth above 1.5x ADI's 0.76%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
0.02%
Debt growth far above ADI's 0.03%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
1.30%
R&D dropping or stable vs. ADI's 4.89%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
No Data
No Data available this quarter, please select a different quarter.